References
- 1.ALIBERTI S, BRAMBILLA AM, CHALMERS JD, CILLONIZ C, RAMIREZ J, BIGNAMINI A, PRINA E, POLVERINO E, TARSIA P, PESCI A, TORRES A, BLASI F, COSENTINI R. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res. 2014 Mar 4;15(1):27.
- 2. SIEMIENIUK RA, BARTOSZKO JJ, ZERAATKAR D, KUM E, QASIM A, MARTINEZ JPD, IZCOVICH A, LAMONTAGNE F, HAN MA, AGARWAL A, AGORITSAS T, AZAB M, BRAVO G, CHU DK, COUBAN R, DEVJI T, ESCAMILLA Z, FOROUTAN F, GAO Y, GE L, GHADIMI M, HEELS-ANSDELL D, HONARMAND K, HOU L, IBRAHIM Q, KHAMIS A, LAM B, MANSILLA C, LOEB M, MIROSHNYCHENKO A, MARCUCCI M, MCLEOD SL, MOTAGHI S, MURTHY S, MUSTAFA RA, PARDO-HERNANDEZ H, RADA G, RIZWAN Y, SAADAT P, SWITZER C, THABANE L, TOMLINSON G, VANDVIK PO, VERNOOIJ RW, VITERI-GARCÍA A, WANG Y, YAO L, ZHAO Y, GUYATT GH, BRIGNARDELLO-PETERSEN R. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.
- 3. ASSIMAKOPOULOS SF, MARANGOS M. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome. Med Hypotheses. 2020;140:109778.
- 4. du PREEZ HN, ALDOUS C, KRUGER HG, JOHNSON L. N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19. Adv Pharmacol Pharm Sci. 2022;2022:4555490.
- 5. WAN X, WANG W, LIU J, TONG T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
- 6. AVDEEV SN, GAYNITDINOVA VV, MERZHOEVA ZM, BERIKKHANOV ZG. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J Infect. 2022;84(1):94–118.
- 7. GAYNITDINOVA V.V., AVDEEV S.N., MERZHOEVA Z.M., BERIKKHANOV Z.G., MEDVEDEVA I.V., GORBACHEVA T.L. N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia. PULMONOLOGIYA. 2021;31(1):21–29.
- 8. MOUSAPOUR P, HAMIDI FARAHANI R, MOSAED R, ASGARI A, HAZRATI E. Efficacy and safety of acetylcysteine for the prevention of liver injury in COVID-19 intensive care unit patients under treatment with remdesivir. Gastroenterol Hepatol Bed Bench. 2022;15(3):241–248.
- 9. TAHER A, LASHGARI M, SEDIGHI L, RAHIMI-BASHAR F, POOROLAJAL J, MEHRPOOYA M. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep. 2021;73(6):1650–1659
- 10. de ALENCAR JCG, MOREIRA CL, MÜLLER AD, et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2021;72(11):e736–e741.
- 11. IZQUIERDO JL, SORIANO JB, GONZÁLEZ Y, et al. Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Sci Prog. 2022;105(1):368504221074574.
- 12. ASSIMAKOPOULOS SF, ARETHA D, KOMNINOS D, et al. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infect Dis (Lond). 2021;53(11):847–854.
- 13. FAVERIO P, REBORA P, ROSSI E, et al. Impact of N-acetyl-l-cysteine on SARS-CoV-2
- 14. KHOONSARI M, ZAMANI F, KARBALAIE NIYA M H, HEMMASI G, AJDARKOSH H, et al. Liver Enzymes and Inpatient Deaths in COVID-19 Hospitalized Patients. Hepat Mon. 2020;20(11):e109076.
- 15. CARRILLO HERNANDEZ-RUBIO J, SANCHEZ-CARPINTERO ABAD M, YORDI LEON A, et al. Outcomes of an intermediate respiratory care unit in the COVID-19 pandemic. PLoS One. 2020;15(12):e0243968.
- 16. TSERMPINI EE, GLAMOČLIJA U, ULUCAN-KARNAK F, REDENŠEK TRAMPUŽ S, DOLŽAN V. Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review. Antioxidants (Basel). 2022;11(8):1609.
- 17. du PREEZ HN, ALDOUS C, KRUGER HG, JOHNSON L. N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19. Adv Pharmacol Pharm Sci. 2022;2022:4555490.
- 18. JIANG C, ZOU J, LV Q, YANG Y. Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Palliat Med. 2021;10(6):6564–6576.
- 19. POOLE P, SATHANANTHAN K, FORTESCUE R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5(5):CD001287.